Novo Nordisk’s Wegovy Wins FDA Approval for Rare Liver Disease
Novo Nordisk’s Wegovy has received US approval to treat a rare liver disease called metabolic dysfunction-associated steatohepatitis (MASH), affecting around 5% of US adults with moderate to advanced liver fibrosis. This makes Wegovy the first GLP-1 class therapy cleared for MASH. The approval boosts the drug’s applications beyond diabetes and obesity treatment, expanding its presence … Read more